



October 3, 2022

Name of Company: Meiji Holdings Co., Ltd.

Name of Representative: Kazuo Kawamura, CEO, President and Representative Director

Code Number: 2269, Prime Market, Tokyo Stock Exchange

## Notice concerning Adoption as “Developing Biopharmaceutical Manufacturing Sites to Strengthen Vaccine Production Project” Offered by METI

Meiji Holdings Co., Ltd. is pleased to announce that its subsidiary, KM Biologics Co., Ltd., has been selected as a company for the Developing Biopharmaceutical Manufacturing Sites to Strengthen Vaccine Production Project (hereinafter "the Project") offered by the Ministry of Economy, Trade and Industry (METI).

Also, its subsidiary, Meiji Seika Pharma Co., Ltd., has been selected for the Project for its construction plan of an mRNA manufacturing plant. The plan was jointly applied with ARCALIS, Inc.

The target of the Project is to establish a system that will enable the prompt start of vaccine production in Japan in the event of an infectious disease pandemic (hereinafter “emergencies”) by:

- 1) Securing dual-use facilities that can produce biopharmaceuticals to meet the needs of companies during normal times and switch to vaccine production during emergencies.
- 2) Providing support for formulation and filling facilities that are essential to vaccine production, as well as for manufacturing facilities for component materials and other parts necessary for drug production.

The Meiji Group has strengths in the infectious diseases area. The adoption of this Project will establish and strengthen a domestic production and supply system capable of producing and supplying the necessary vaccines to the public promptly and reliably against potential outbreaks of new infectious diseases.

The impact of this matter on consolidated earnings forecasts for the fiscal year ending March 31, 2023 is expected to be minor.

#####